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Physical therapists have a unique role in both prevention of venous thromboembolism
(VTE) through the promotion of early mobility and physical activity and diagnosis through
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information regarding pathophysiology of coagulopathy associated with COVID-19 and
applies VTE clinical practice guidelines to COVID-19 in order to provide guidance on
physical therapist management.
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Coagulopathy and COVID-19

P

Pathophysiology of COVID-19
Coagulopathy
The COVID-19 virus causes an acute inflammatory
response throughout the entire body upon entering via
the angiotensin-converting enzyme 2 (ACE2) receptors,1,2
which are expressed in multiple organs and endothelial
cells.1–4 In fact, some have referred to COVID-19 as COVID
endothelialitis due to the effect the virus has on the
endothelium of all tissues in the body and especially on
the arterial and venous endothelium.2,3 The clinical
presentation of COVID-19 varies greatly among patients,
with some expressing only mild symptoms, whereas
others have a severe presentation that can progress to
critical illness.4 Patients admitted to the hospital with
COVID-19 have an increased risk for VTE and
microvascular thrombosis.4,5,6 Venous thromboembolism
includes deep vein thrombosis (DVT), pulmonary
embolism, or both. Patients with COVID-19 are thought to
be at an increased risk of VTE secondary to a hyperactive
immune response resulting in a cytokine storm that
occurs with profound systemic inflammation.5,7,8 Zhai6
reported that approximately 20% of patients with
COVID-19 present with severe coagulation abnormalities,
but it could be present in all of the cases of severe and
critical illness. Due to a lack of awareness of these
coagulation issues early on, VTE may have been present in
more patients seen across the world with COVID-19 and
potentially was the cause of some of the unexplained
deaths.6,9
The coagulation abnormalities found in COVID-19 appear
as a hypercoagulable state, including widespread
microvascular thromboses that compromise the blood
flow to small blood vessels in multiple organs.10
Retrospective studies of medical records from hospitalized
patients who tested positive for COVID-19 have revealed
that COVID-19 coagulopathy presents with profoundly
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elevated fibrinogen and D-dimer, abnormalities in platelet
counts, and (in some cases) mild prolongation in
prothrombin time (PT).11
Elevations in fibrinogen and D-dimer are common with
severe inflammatory disease and are associated with
significant clotting and even disseminated intravascular
coagulopathy (DIC).3 Tang et al10 concluded that 71% of
the patients with COVID-19 who died met the
International Society on Thrombosis and Haemostasis
(ISTH) criteria for DIC, compared with only 0.6% of the
survivors.
Greatly elevated D-dimer (3.5-fold increase above normal)
and elevated fibrinogen (1.9 X normal levels) in patients
with COVID-19 were significantly related to an increased
risk of mortality.8 ,10 Despite the association between
elevated D-dimers and poor patient prognosis,10 elevated
D-dimer is so common in hospitalized patients with
COVID-19 that elevated D-dimers alone would be
insufficient to warrant further testing for VTE, including a
duplex ultrasound. In a meta-analysis of 9 studies
including 1779 patients with COVID-19, Lippi et al12
found the platelet count was significantly lower in patients
with severe disease (mean = 31,000/μL), with an even
lower platelet count associated with mortality
(mean = 22,000/μL).12 As there are no data on laboratory
values from patients who tested positive for COVID-19 but
were not hospitalized, identifying less severe patients at
increased risk for VTE is more challenging.

Risk Factors and Prevalence
of Coagulopathy
Although available data on COVID-19 are still sparse, the
evidence in support of this severe COVID-19
coagulopathy continues to emerge. In the study by Helms
et al13 from France, thrombus was found in dialysis
catheters and extracorporeal membrane oxygenation
(ECMO) catheters. In one autopsy study, 4 out of 21
individuals demonstrated significant pulmonary embolism,
5 of 21 had microthrombi in alveolar capillaries, and 3 had
thrombotic microangiopathy in glomerular capillaries.13 ,14
In multiple studies and in spite of anticoagulation, VTE
occurred in 27% of the population hospitalized with
severe COVID-19.15 Microvascular thrombosis has also
been found in small vessels, including the pulmonary
capillaries, distal digits in extremities, and other
organs.14 ,16 Microvascular thrombosis is a potential cause
of elevations in cardiac enzymes (troponin and proBNP),
need for dialysis due to renal dysfunction or failure, and
other organ dysfunctions.14 ,16
The risk of VTE is increased in all individuals who are
critically ill but appears to be even higher in those with
COVID-19.14 ,15 In addition to the systemic inflammation
already mentioned, patients with COVID-19 may have
additional risk factors for VTE if certain medical
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hysical therapists are increasingly working
with individuals who have been diagnosed with
coronavirus disease 2019 (COVID-19), including
patients in the acute phase while hospitalized and during
the recovery phase in the inpatient rehabilitation, skilled
care, home health, and outpatient settings.1 The effect of
the virus on the respiratory system appears to range from
a simple respiratory tract infection to acute respiratory
distress syndrome (ARDS) with multiorgan failure.1 People
with COVID-19 may also develop coagulopathy that can
lead to venous thromboembolism (VTE) and
microvascular thrombosis throughout the body.1 Physical
therapists have a unique role in both the prevention of
VTE through the promotion of early mobility and physical
activity and diagnosis through discovery of signs and
symptoms of VTE. Therefore, it is critical that physical
therapists are aware of the clinical implications of this
unique coagulopathy and the prevalence of VTE in
patients diagnosed with and recovering from COVID-19.

Coagulopathy and COVID-19

Prevention of Venous Thromboembolism
Clinical practice guidelines currently exist, notably the
guideline from the American College of Chest Physicians,
to provide direction on the management and prevention
of venous thromboembolism (VTE); however, these
guidelines do not specifically address the unique concerns
of COVID-19 given its novel status.22 When the disease
first emerged in other countries (China, South Korea),
routine chemical prophylaxis was not provided.8,9
However, since learning about the risk of thrombosis and
coagulopathy, prophylactic doses of anticoagulation are
now a standard part of the protocol on admission for
individuals diagnosed with COVID-19, unless there is an
absolute contraindication to anticoagulation. If
contraindication to anticoagulation is present, then
mechanical prophylaxis (intermittent pneumatic
compression) is strongly recommended.4 This practice
was instituted based upon clinical evidence of the risk of
thrombotic events described above, as there have not been
any randomized clinical trials to substantiate this practice
to date. In addition, assessment of VTE risk of all patients
with COVID-19 on admission is the current
recommendation, as elevated risk may require a
therapeutic dose of anticoagulation rather than a
prophylactic dose.3,4 Current studies are reporting the use
of the IMPROVE and Padua risk assessment models
(RAMs) for patients with COVID-19, and the Caprini Risk
Assessment for all patients who have surgery or trauma.4
These RAMs include additional risk information—such as
history of active cancer or heart failure and severe loss of
mobility—that contribute to the clinical picture of the
patient with COVID-19.
As mentioned above, all patients with COVID-19 admitted
to the hospital should be receiving prophylactic
anticoagulation6 ; however, there are cases of increased
risk or medical team preference where patients are
receiving therapeutic doses prophylactically.6
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Unfractionated heparin (UFH) is a common treatment
option because of its short half-life and reduced
drug–drug interactions with investigational COVID-19
therapies and is the primary drug to be used when the
patient has decreased creatinine clearance (renal
dysfunction).3,23,24 The need to reduce exposure to health
care providers and use of PPE equipment, however, may
present challenges given the frequent blood draws
required with UFH. For this reason, if it is deemed
unlikely a patient will be requiring a procedure, low
molecular weight heparin (LMWH) may be preferable.
As recommended in the Role of Physical Therapists in the
Management of Individuals at Risk for or Diagnosed With
Venous Thromboembolism: Evidence-Based Clinical
Practice Guideline,23 physical therapists should advocate
for a culture of mobility and physical activity unless
medical contraindications for mobility exists. This key
action statement applies to individuals with COVID-19.
Patients with COVID-19 should be encouraged to maintain
physical activity. For those managing symptoms at home,
performing short bouts of aerobic and body weight
resistance training may help prevent losses in function,
benefit the immune system,25 and decrease the risk of
VTE.23 Patients in the hospital who are medically stable
should be encouraged to get out of bed, move around
their room, and, when appropriate, follow a prescribed
exercise program.23 Supervision by a physical therapist,
with monitoring of vital signs, may be appropriate in
some cases. Bed rest should be discouraged to maintain
physiological function and to lower the risk of VTE.23
Although it is outside the scope of this article, it is
important to note that the coagulation abnormalities may
also be affecting the arterial side of the vascular system,
causing stroke, myocardial injury, and peripheral arterial
embolisms.15,26,27 At this time, the prevalence of arterial
thrombosis does not appear to be as high as VTE, but
there have been some alarming reports of stroke as the
presenting sign of COVID-19 in a small group of young
patients.26,27 For these reasons, health care practitioners
should consider COVID-19 a risk factor for thrombotic
complications and be vigilant in their assessment of
patients presenting with risk of or signs/symptoms of
cerebral vascular injury or myocardial injury.

Indicators of Coagulopathy
and Likelihood Assessment
For physical therapists treating this patient population
who encounter physical signs suggestive of lower
extremity (LE) DVT (ie, pain, unilateral swelling, warmth,
tenderness below knee), the clinical practice guidelines
(CPG) on VTE should be following, and the Wells criteria
should be used to determine the likelihood of LE DVT.23 If
an upper extremity DVT is suspected (Table 1), the
Constans criteria should be utilized.28 Although all
providers should remain vigilant in looking for these
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interventions were required, such as mechanical
ventilation and central venous catheters. There are reports
of nutritional deficiencies and liver dysfunction that can
interfere with the production of coagulation factors.17– 20
Furthermore, patients who are older with multiple
comorbidities are more likely to experience more severe
clinical symptoms of COVID-19, adding additional risk
factors for VTE to the clinical picture.6 Finally, the limited
supply of personal protective equipment (PPE) has forced
facilities to limit health care workers’ interactions with
patients who have COVID-19, including those of physical
therapists. Concerns regarding emergent needs to access
patients who pull out lines and tubes have led the medical
team to favor sedation for protection of both patient and
worker, leading to increased amount and length of
sedation.21 The culmination of these decisions has
ultimately reduced the total mobility of these patients,
therefore increasing the risk of VTE.

Coagulopathy and COVID-19
Table 1.
Signs and Symptoms of Venous Thromboembolism (VTE)23 ,30, 33
Signs and Symptoms

Upper Extremity DVT

X

X

Swelling/edema

X

X

Warmth

X

Discoloration/redness

X

Cyanosis

Pulmonary Embolism

X

Dilation of superficial veins

X

X

HRrest > 100 bpm

X

Dyspnea

X

Chest pain

X

Presyncope/syncope

X

Hemoptysis

X

common DVT signs, the increased risk of VTE in patients
with COVID-19 most often presents as pulmonary
embolism rather than DVT.29,30 If there are signs and
symptoms consistent with pulmonary embolism—
including dyspnea, tachycardia, chest pain, presyncope or
syncope, or hemoptysis—the physical therapist should
use a clinical prediction rule (eg, Geneva score)31,32 for
pulmonary embolism or the Wells criteria for pulmonary
embolism) to determine likelihood of pulmonary
embolism.31 It is important to note that, although the
clinical manifestations of pulmonary embolism can be
variable, other common signs may warrant the use of a
clinical prediction rule, such as hemodynamic instability,
hypoxemia, hypocapnia, electrocardiographic evidence of
right ventricular strain, or sinus tachycardia.31

pulmonary embolism and referred to emergency care.30
Patients that present with right ventricular dysfunction on
transthoracic echocardiogram or computed tomographic
pulmonary angiography, elevated cardiac biomarkers,
and/or PESI > III (sPESI ≥1) should be considered low
intermediate risk for early death (in-hospital or 30-day).31
If patients present with the aforementioned findings and
elevated cardiac troponin levels, this would increase the
patient’s risk of early death to high intermediate risk.31 If
the patient is hemodynamically stable, lacks evidence of
right ventricular dysfunction, has normal cardiac
troponins, and has PESI I or II (sPESI = 0), the patient is
at a low risk of early death.31

When applying clinical judgment in the presence of
patients with COVID-19, it may be helpful to discern the
overall risk profile. In addition to using the insights gained
from clinical imaging—such as echocardiography (to
assess right ventricular strain) and computed tomographic
pulmonary angiography, laboratory biomarkers including
D-dimers, markers of myocardial injury (ie, troponin) and
right ventricular dysfunction (ie, B-type natriuretic peptide
(BNP) and N-terminal (NT)-proBNP)—physical therapists
can perform a clinical risk assessment screen to determine
pulmonary embolism severity and risk of early death. The
2019 European Society of Cardiology Guidelines
recommend the use of the Pulmonary Embolism Severity
Index (PESI) or simplified PESI (sPESI) for risk
stratification, which can be used by physical therapists to
help direct clinical decision making.31

Finally, recommendations for length of medical treatment
for VTE post–COVID-19 have been presented in 3
guidelines recommending up to 45 days of extended
prophylaxis after hospitalization for those with severe or
critical cases.3 ,4 ,6 Individuals who had a documented VTE
during hospitalization are recommended to continue the
therapeutic dosage of the prescribed anticoagulant for
3 months and reassessed after that time.3 ,4 ,6 Table 2 lists
current anticoagulation doses regularly reported in the
treatment of COVID-19 patients. Dosages may be adjusted
posthospitalization based upon presence of VTE during
hospitalization, but direct oral anticoagulants (DOACs)
often have been prescribed posthospitalization due to lack
of need to be followed for blood therapeutic levels and
due to inability of patients to have caregivers to
administer shots.22

At the earliest possible stage, it is critical to identify
patients that may be presenting with massive pulmonary
embolism. Any patient that has hemodynamic instability
should be immediately considered to have a high-risk

For mild-to-moderate COVID-19, patients should be
instructed on the importance of hydration and mobility
for prevention of VTE and to watch for new signs of VTE.
Therapists can use the Physical Activity Guidelines for
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Long-Term Management
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Lower Extremity DVT

Pain/tenderness

Coagulopathy and COVID-19

Clinical decision algorithm for venous thromboembolism (VTE) screening in patients with COVID-19. LE DVT = deep vein thrombosis of the
lower extremity; UE DVT = deep vein thrombosis of the upper extremity.

Table 2.
Anticoagulation Medications Commonly Used in the Outpatient Setting With COVID-1934,35
Dose

Low Molecular Weight Heparin
Enoxaparin (Lovenox)

Direct Oral Anticoagulants
Xarelto

Eliquis

Prophylactic dose

0.5 mg/kg daily, or approximately
40 mg/day

10 mg once daily

2.5 mg twice daily

Therapeutic dose

0.75 mg/kg twice daily

15 mg twice daily for 3 weeks,
then 20 mg once daily

10 mg twice daily for 1 week, then
5 mg twice daily

Americans as a reference for activity guidelines.31 In
individuals who were considered to be at increased risk
for VTE with mild-to-moderate COVID-19, continuation of
some dosage of anticoagulation is recommended, as well
as instruction on how to avoid sedentary behavior and
appropriate exercise prescription to keep these
individuals active.6 Anticoagulation may be necessary for
up to 3 months post–COVID-196 ; therefore, health care
professionals treating patients post–COVID-19 should
assess presence of and compliance with medications to
decrease risk of VTE. Physical therapists should
acknowledge the elevated risk of VTE in this population
due to the coagulopathy associated with COVID-19 and

2020

the fact that, even with anticoagulation, some individuals
will still experience a VTE.15

Application to Clinical Practice
Physical therapists should be aware of coagulopathy
and elevated VTE risk in patients diagnosed with
and recovering from COVID-19, particularly those patients
who were hospitalized with severe or critical illness. For
this reason, all patients who test positive for COVID-19
should be screened regularly for signs and symptoms
of VTE (Table 1), and immediate action should be taken
if the physical therapist suspects new VTE.23,30,33 A clinical
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Figure.

Coagulopathy and COVID-19
decision algorithm to help guide physical therapists as
they encounter patients with COVID-19 who present with
suspected VTE is found in the Figure. As shown in the
Figure, mobility is encouraged once the individual is stable
and medically managed, in most cases with anticoagulants.

In those individuals who are currently being treated for
VTE, the current medical management should be
identified on the initial visit, including anticoagulation,
length of treatment, or the need for mechanical
intervention.22 Practitioners need to remember that even
with prophylaxis medications, the risk of VTE is still
present.15 Patients need to be educated on the risk for
bleeding with anticoagulants and how to take precautions,
especially when they cut themselves or fall.
Knowing the risks for VTE and the appropriate treatment
are essential parts of physical therapist assessment and
intervention because this knowledge could save lives. As
movement specialists, physical therapists need to
encourage mobilization to help prevent the initial VTE and
to help decrease the risk of a recurrent VTE. The unique
nature of COVID-19 may force us to deliver physical
therapy services within a confined space due to isolation
protocols, or we may have to provide education instead of
hands-on treatment to keep ourselves safe. However, it is
the role of physical therapists to promote a culture of
mobility to help patients with COVID-19 maintain
function and possibly decrease their risk of VTE.23
We are learning more information on this critical illness
daily that may provide better information on the
mechanisms involved and possible markers for screening
those patients more likely to present with coagulopathies.
Until more is known, our best course of action is to use
previously published clinical practice guidelines on the
prevention, screening, and management of those with VTE
combined with our clinical expertise.22,23,31 Physical
therapists need to stay current with the literature as more
is published and information is shared about COVID-19
and coagulopathy.
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